Response to [(177)Lu]Lu-PSMA radioligand therapy in metastatic castration-resistant prostate cancer patients presenting with only lymph node metastases

[(177)Lu]Lu-PSMA radioligand therapy (PSMA-RLT) is a promising therapy for patients with metastatic castration-resistant prostate cancer (mCRPC) and offers a survival benefit particularly to patients with only lymph node metastases. We therefore sought to evaluate the clinical outcome of this therap...

Descripción completa

Detalles Bibliográficos
Autores principales: Zisser, Lucia, Yu, Josef, Oszwald, André, Wollenweber, Tim, Kretschmer-Chott, Elisabeth, Grubmüller, Bernhard, Kramer, Gero, Shariat, Shahrokh F., Mitterhauser, Markus, Vraka, Chrysoula, Hacker, Marcus, Haug, Alexander R., Rasul, Sazan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lippincott Williams & Wilkins 2022
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9575560/
https://www.ncbi.nlm.nih.gov/pubmed/36120814
http://dx.doi.org/10.1097/MNM.0000000000001611

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9575560/
https://www.ncbi.nlm.nih.gov/pubmed/36120814
http://dx.doi.org/10.1097/MNM.0000000000001611

Ejemplares similares